✽ Our philosophy
“While molecules form the basis of medicines, it's the ingenuity of people that drives breakthroughs.”
AI, physics data and robotised labs are reshaping drug development. Our greatest strength is still the collaborative, inventive minds that move our programs forward.
The team
Vincent Lit, PhD
Founder & CEO
Translated his Leiden University PhD discoveries into a company
built to make an impact in medicine development.
LinkedIn ↗
Rana Ramadan
Translational Scientist
Her PhD focused on the mechanisms that drive treatment resistance
in oncology, and on translating those insights into therapies for
patients.
LinkedIn ↗
Arian Khoshchin, MSc
Founder & CDO
A start-up operator trained in biopharmaceutical sciences and
industrial pharmacy, with a decade of biopharma development
experience.
LinkedIn ↗
Helena Ehren, PhD
Process & Analytical Scientist
A passionate organic chemist whose PhD focused on glycans and the
glycan-metabolising apparatus.
LinkedIn ↗
Advisory team — world-class expertise
Prof. Dr. Adam Cohen
Clinical Advisor
World-class clinical pharmacologist and physician. Founder of CHDR
in Leiden and former chair of the Netherlands competent authority
for clinical trials.
Prof. Dr. Johan van der Vlag
Scientific Advisor
Professor of Experimental Nephrology at Radboud, whose pioneering
work established heparanase as a key driver of renal damage and
proteinuria, with a focus on DKD.
Prof. Dr. Hiddo Heerspink
Clinical Advisor
Professor of clinical trials and personalised medicine at the
UMCG; led landmark renal trials including DAPA-CKD and FIND-CKD.
Founding advisors — pivotal to our technology
Prof. Herman Overkleeft
Technology Advisor
Professor of chemical biology at Leiden University and an expert
in glycosidase chemical biology; founder of Azafaros.
Prof. Gideon Davies
Structural Biology Advisor
Renowned for his work on carbohydrate-active enzymes and the
mechanistic basis for catalysis.
Dr. Liang Wu
Scientific Advisor
A structural biologist of sugar-processing enzymes, trained at
UCL, Cambridge and York.
Alessandro Noseda, MD
Scientific Advisor
Medical doctor and global drug-development leader who advanced a
previous class of heparanase inhibitors to phase 2.